FDA Frowns on Evolus' Botox Rival
May 15, 2018
The U.S Food and Drug Administration did not approve DWP-450, Evolus Inc's rival product to Allergan Plc's Botox, due to chemistry and manufacturing issues.
As a result, the company pushed its estimate for the launch of the drug to the spring of next year. Read more here.
Facebook Comments